mRNA-1010.4 / Moderna - LARVOL DELTA

A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults (clinicaltrials.gov) - P1/2 | N=1231 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Trial completion date: Dec 2023 ➔ Nov 2024 | Trial primary completion date: Dec 2023 ➔ Nov 2024

Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults (clinicaltrials.gov) - P2 | N=270 | Completed | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults (clinicaltrials.gov) - P1/2 | N=1231 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Aug 2023 ➔ Dec 2023

Enrollment closed • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults (clinicaltrials.gov) - P2 | N=270 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Trial primary completion date: Sep 2023 ➔ Dec 2023

Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults (clinicaltrials.gov) - P2 | N=270 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults (clinicaltrials.gov) - P2 | N=270 | Recruiting | Sponsor: ModernaTX, Inc.

New P2 trial • Infectious Disease • Influenza • Respiratory Diseases